Suppr超能文献

单克隆抗体的生理药代动力学(PBPK)模型的开发以及放射性标记单克隆抗体在人和小鼠中的PBPK模拟。

Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody.

作者信息

Heiskanen Tomi, Heiskanen Tomas, Kairemo Kalevi

机构信息

Xemet Co. Ltd., Tikasniitynkuja 7, 02200, Espoo. Finland.

出版信息

Curr Pharm Des. 2009;15(9):988-1007. doi: 10.2174/138161209787581968.

Abstract

Physiology based pharmacokinetic (PBPK) modeling and simulation is a useful method for prediction of biodistribution of both macromolecules and small molecules. It can enhance our understanding of the underlying mechanisms of biodistribution and hence may help in rational design of macromolecules used as diagnostic and therapeutic agents. In this review we discuss PBPK modeling and simulation of a radiolabelled Monoclonal Antibody ((111)In-DOTA-hAFP31 IgG) ("MAB") in mice without tumor and in a human with tumor. This study is part of Xemet Co.'s effort to develop a more accurate and reliable PBPK model and simulation platform, which is applicable both for small molecules and macromolecules. The simulated results were fitted to experimental time series data by varying parameters which were not fixed a priori. It was demonstrated that the PBPK model describes the main features of the pharmacokinetics of the studied systems. It was also shown that simulation can be used for evaluating the parameters of the system and scaling up the pharmacokinetics of MAB from mice to man. We identified several areas of improvement and further development needed to improve the accuracy of PBPK simulation for MAB and other macromolecules. It was concluded that the transvascular permeabilities are the most important parameters and more research is needed to enable prediction of permeabilities from molecular characteristics of macromolecules. It would also be necessary to understand better and describe with a more detailed model the microstructure of the tumor and to measure or predict the antigen concentration in tumor. Non-specific, non-saturable binding in other organs/tissues should be understood better and the kinetic constants of the binding should be measured experimentally. Although the metabolism and clearance were neglected in this study they need to be included in more detailed studies. Also the intracellular trafficking of macromolecules, which was not included in this study, shall be included in the more accurate models.

摘要

基于生理学的药代动力学(PBPK)建模与模拟是预测大分子和小分子生物分布的一种有用方法。它可以增强我们对生物分布潜在机制的理解,因此可能有助于合理设计用作诊断和治疗剂的大分子。在本综述中,我们讨论了放射性标记的单克隆抗体((111)In - DOTA - hAFP31 IgG)(“MAB”)在无肿瘤小鼠和有肿瘤人类中的PBPK建模与模拟。这项研究是Xemet公司开发更准确可靠的PBPK模型和模拟平台工作的一部分,该平台适用于小分子和大分子。通过改变事先未固定的参数,将模拟结果与实验时间序列数据进行拟合。结果表明,PBPK模型描述了所研究系统药代动力学的主要特征。还表明,模拟可用于评估系统参数,并将MAB的药代动力学从小鼠扩大到人类。我们确定了几个需要改进和进一步发展的领域,以提高MAB和其他大分子PBPK模拟的准确性。得出的结论是,跨血管通透性是最重要的参数,需要更多研究以根据大分子的分子特征预测通透性。还需要更好地理解并用更详细的模型描述肿瘤的微观结构,并测量或预测肿瘤中的抗原浓度。应更好地理解其他器官/组织中的非特异性、非饱和结合,并通过实验测量结合的动力学常数。尽管本研究中忽略了代谢和清除,但在更详细的研究中需要将它们包括在内。此外,本研究未包括的大分子细胞内运输也应纳入更准确的模型中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验